Andy Laccetti MD, MS

GU Medical Oncologist at @Perlmutter_CC NYU Langone. Director of Quality. Investigator of novel PCa therapeutics and patient monitoring systems.

[UroToday.com @urotoday]

Efficacy and safety of darolutamide monotherapy in patients with CSPC after BCR: 52 week results from #ARAMON. Presentation by @alaccetti @MSKCancerCenter. #GU26 written coverage by @zklaassen_md @GACancerCenter > https://t.co/ufH0NfawQV @ASCO #ASOCGU26

[Michael Shusterman, MD @guildsman]

We are recruiting @Perlmutter_CC ! Feel free to DM me for details! Gastrointestinal Medical Oncology Faculty Physician - focused at our NYU Langone Hospital – Long Island campus in Mineola NY. Fantastic opportunity to join growing program, including the new GI Cancer Center.

[UroToday.com @urotoday]

Shifting from surgery to chemoablation for low-grade #BladderCancer treatment. @KSMurrayUro @NYUUrology joins @zklaassen_md @GACancerCenter to discuss chemoablation with mitomycin (ZUSDURI™) for low-grade intermediate-risk #NMIBC. The discussion covers practical implementation details, including the gel formulation, catheter placement, and the six-week treatment course without maintenance therapy. #WatchNow > https://t.co/3CSYg3JCGi

[Uromigos @Uromigos]

🚨 In this week's episode Michael Morris from MSKCC joins Brian and Tom for an in-depth review of ARPI development across the spectrum of prostate cancer.

🍎 Apple Podcasts: https://t.co/7i5LrKpjUU
🎧Spotify: https://t.co/2cTzBkc62Z

[David H Aggen, MD PhD @Dr_Aggen]

Variant Histologies of Bladder Cancer - They are more like different types of music with distinct
- openers (neoadjuvant therapy)
- headliners (front line therapy)

Learn more ahead of #Uromigoslive25 @Uromigos

[UroToday.com @urotoday]

ADT remodels the tumor microenvironment from immunologically cold to hot. Matthew Dallos, MD @MSKCancerCenter joins @AndreaMiyahira @PCFnews in this discussion of how androgen deprivation therapy reshapes the immune landscape in localized #ProstateCancer. #WatchNow > https://t.co/DFlGl0vZ9v

[Sean McBride @seanmmcbride]

This was the date set in the end of year (2024) appropriations bill passed by the prior Congress and signed by President Biden. This new Congress was always going to have to provide for a statutory extension. We knew this in December. I’m confident Congress will act. Our seniors deserve it. But speak up and speak out out to your Reps and Senators. #telehealth #medtwitter #radonc

[Zach Klaassen @zklaassen_md]

DARO monotherapy in CSPC after BCR: ARAMON lead-in phase results @urotoday @BayerOncMed #GU25

☑️n=23
☑️At wk 12: mean % ⬆️ in T from B/L was 53.5% (95%CI, 33.4–76.5)
☑️PSA responses:
- <0.2: 65.2%
- PSA50: 100%
- PSA90: 78.3%
☑️Feminizing TEAEs - 18/23 pts:
- Gr 1 or 2: n=17
- Dose modif: n=4
- Tamoxifen for gynecomastia: n=2

[David H Aggen, MD PhD @Dr_Aggen]

Everyone in academic medicine is hopeful the pause at NIH will be temporary. The research funding pause will affect post doctoral
researchers, technicians, and academic research efforts across the United States.

https://t.co/OWYKGALY4e

[MSK Library @MSKLibrary]

Synapse: Your Connection to our MSK Authors
Meet: Ritesh Kotecha @KotechaMD
Research Focus: Medicine; Assistant Attending

Sample site impacts RNA biomarkers for renal cell carcinoma
#RenalCellCarcinoma #CancerBiomarkers #RNAResearch

https://t.co/uAv9bQvTK2

[Andy Laccetti MD, MS @alaccetti]

https://t.co/s1g3whRVK7

[UroToday.com @urotoday]

The efficacy and resistance-breaking potential of EPI-7386 masofaniten in castration-resistant #ProstateCancer. @alaccetti @MSKCancerCenter joins @zklaassen_md @GACancerCenter discussing the continuous effort to refine hormonal therapy in #PCa management &gt; https://t.co/2XdNrgusyy

[UroToday.com @urotoday]

Dual action hormone therapy targeting two parts of the androgen receptor simultaneously shows tolerability and early efficacy in phase I trial. @alaccetti @MSKCancerCenter and @DrRanaMcKay @UCSanDiego discuss recent advancements in #mCRPC treatments &gt; https://t.co/hqEpfHQs2b

[Jad Chahoud @JadChahoud]

‼️ This combination IIT for pts w refractory penile cancer supported by @GSKUS is accruing pts @MoffittNews @SpiessPhilippe and soon at @MDAndersonNews @CurtisPettaway1 and @uscnorris please offer this option to your pts and reach out w questions @GTumors

[OncLive.com @OncLive]

Masofaniten Plus Enzalutamide Demonstrates Safety and Durable Responses in mCRPC @alaccetti @MSKCancerCenter @myESMO #ESMO23 #pcsm https://t.co/K7iMwlnczu

[The PCCTC @ThePCCTC]

We are pleased to announce the PCCTC-managed study of EPI-7386 in combination with enzalutamide in subjects with metastatic prostate cancer has entered phase 2. For more information visit: https://t.co/KlW3EYyvoO

[UroToday.com @urotoday]

ADT interruption in patients responding exceptionally to AR-pathway inhibitor in #mHSPC: A-DREAM. @AtishChoudhury and @CaPsurvivorship @DanaFarber discuss the right balance of treatment duration for patients with metastatic prostate cancer &gt; https://t.co/adsrTa9GY1

[Oncology Times @OncologyTimes]

Andrew Laccetti, MD, MS, at @MSKCancerCenter underscores “to date, androgen receptor (AR) pathway inhibitors either competitively antagonize the receptor via the ligand-binding domain or block androgen synthesis.” https://t.co/gKDDYBRDua @alaccetti #ESMO23

[Zach Klaassen @zklaassen_md]

Phase 1/2 Trial: Oral EPI-7386 + Enza vs Enza Alone in mCRPC: Ph 1 Results #ESMO23 @urotoday @alaccetti

📍To date, n=18
📍Safety: consistent w/ 2nd-gen antiandrogens
📍PK results: Enza minimally impacted by EPI-7386 --> full dose Enza (160 mg) in cohort 4
📍Evaluable data:
-PSA50: 88%
-PSA90: 69%
-PSA < 0.2 ng/mL: 56%

[OncLive.com @OncLive]

Next-Generation Aniten Masofaniten Gains Momentum in mCRPC @alaccetti @MSKCancerCenter #pcsm https://t.co/QMOrynmxRl